New data suggests 225Ac-PSMA-617 radioligand therapy could improve overall survival in metastatic prostate cancer patients.
List view / Grid view
metastatic prostate cancer
Drugs recommended for approval by the European Medicines Agency’s human medicines committee included a gene therapy and two generics, among five others.
Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life.
The Committee for Medicinal Products for Human Use (CHMP) recommended eight drugs for approval and nine indication extensions.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy...